Please use this identifier to cite or link to this item: https://ir.swu.ac.th/jspui/handle/123456789/17219
ชื่อเรื่อง: Tpmt*3c as a predictor of 6-mercaptopurine-induced myelotoxicity in thai children with acute lymphoblastic leukemia
ผู้แต่ง: Jantararoungtong T.
Wiwattanakul S.
Tiyasirichokchai R.
Prommas S.
Sukprasong R.
Koomdee N.
Jinda P.
Rachanakul J.
Nuntharadthanaphong N.
Pakakasama S.
Anurathapan U.
Hongeng S.
Sukasem C.
Keywords: ABC transporter subfamily B
cyclophosphamide
cytarabine
drug metabolizing enzyme
mercaptopurine
methotrexate
multidrug resistance associated protein 4
prednisolone
thiopurine methyltransferase
vincristine
acute lymphoblastic leukemia
Article
blood sampling
bone marrow toxicity
child,human
controlled study
cytochemistry
female
gene frequency
genetic association
genetic polymorphism
genetic variability
genotype
human
immunophenotyping
leukocyte count
leukopenia
liver toxicity
maintenance therapy
major clinical study
male
medical record
neutropenia
neutrophil count
platelet count
polymerase chain reaction
preschool child
single nucleotide polymorphism
Thai (people)
thrombocytopenia
วันที่เผยแพร่: 2021
บทคัดย่อ: The response to 6-mercaptopurine (6-MP) can be altered by genetic polymorphisms in genes encoding drug-metabolizing enzymes and drug transporters. The purpose of this study was to investigate the association between genetic polymorphisms of drug-metabolizing enzymes (TPMT 719A > G (*3C), ITPA 94C > A and ITPA 123G > A) and drug transporters (MRP4 912C > A and MRP4 2269G > A) with 6-MP-related myelotoxicity and hepatotoxicity in Thai children with acute lymphoblastic leukemia (ALL). The prescribed dosage of 6-MP and its adverse effects were assessed from medical records during the first 8 weeks and 9–24 weeks of maintenance therapy. Children with the TPMT*1/*3C genotype had a higher risk of leukopenia with an odds ratio (OR) of 4.10 (95% confidence interval (CI) of 1.06–15.94; p = 0.033) compared to wild type (TPMT*1/*1) patients. Heterozygous TPMT*3C was significantly associated with severe neutropenia with an increased risk (OR, 4.17; 95% CI, 1.25–13.90); p = 0.014) during the first 8 weeks. No association was found among ITPA 94C > A, ITPA 123G > A, MRP4 912C > A, and MRP4 2269G > A with myelotoxicity and hepatotoxicity. The evidence that TPMT heterozygotes confer risks of 6-MP-induced myelotoxicity also supports the convincing need to genotype this pharmacogenetic marker before the initiation of 6-MP therapy. © 2021 by the authors. Licensee MDPI, Basel, Switzerland.
URI: https://ir.swu.ac.th/jspui/handle/123456789/17219
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85113156828&doi=10.3390%2fjpm11080783&partnerID=40&md5=2721040f77af5abd598f44c4960462b9
ISSN: 20754426
Appears in Collections:Scopus 1983-2021

Files in This Item:
There are no files associated with this item.


Items in SWU repository are protected by copyright, with all rights reserved, unless otherwise indicated.